Bank of America Upgrades AbbVie to Buy on Skyrizi Performance

On April 30, Bank of America upgraded its rating for AbbVie (ABBV) from Neutral to Buy and raised the price target to $234. The firm cited strong performance in immunology drug Skyrizi and durable growth prospects into the mid-2030s.

By Vardah Gill Fri, May 1, 2026 at 2:21 AM GMT+3 2 min read · Yahoo Finance · April 30, 2026, 23:21 UTC

Bank of America Upgrades AbbVie to Buy on Skyrizi Performance

Tickers: $ABBV

Topics: Analyst Opinion Biotech Dividend Growth Stocks Pharmaceuticals Stock Upgrade

Read the full article at Yahoo Finance

More World news

Centalion Americas Refinances and Upsizes Credit Facility to $3.5 Billion PR Newswire · November 12, 2026, 19:15 UTC
Nvidia Faces Leadership Transition as Jensen Huang Resigns Amid Investigation Seeking Alpha · November 12, 2026, 18:30 UTC
SOLV Energy Reports Record Q3 2026 Results and Raises Full-Year Guidance Motley Fool · November 12, 2026, 19:09 UTC
Clear Secure Reports Strong Q3 Earnings and Raises Full Year Guidance Amid Expansion into Identity Verification CNBC · November 12, 2026, 19:09 UTC
Nectar Launches AI Agent to Automate Influencer Discovery and Outreach TechCrunch · November 12, 2026, 19:11 UTC
Cohen & Company Appoints Daniel Cohen as CEO with $500 Million Revenue Target Seeking Alpha · November 12, 2026, 19:10 UTC
X-Energy Receives Early NRC Construction Permit and Anticipates Dow Investment Decision by 2027 Seeking Alpha · November 12, 2026, 19:10 UTC
Alvotech Shares Decline Following Third Quarter Earnings Miss Seeking Alpha · November 12, 2026, 19:05 UTC
Saga Communications Projects $5.7 Million in 2026 Political Revenue Amid Q4 Growth Seeking Alpha · November 12, 2026, 19:00 UTC
Corteva Forecasts 2026 Operating EBITDA Between $1.1B and $1.125B Amid Brazilian Market Pressures Seeking Alpha · November 12, 2026, 19:00 UTC